Log in

Keros Therapeutics Stock Forecast, Price & News

+1.33 (+1.75 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $77.33
50-Day Range
MA: $61.44
52-Week Range
Now: $77.33
Volume101,545 shs
Average Volume124,212 shs
Market Capitalization$1.56 billion
P/E RatioN/A
Dividend YieldN/A
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KROS



Sales & Book Value

Annual SalesN/A
Book Value$6.48 per share



Market Cap$1.56 billion
Next Earnings Date2/9/2021 (Estimated)
OptionableNot Optionable
+1.33 (+1.75 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KROS News and Ratings via Email

Sign-up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Keros Therapeutics (NASDAQ:KROS) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Keros Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Keros Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Keros Therapeutics?

Wall Street analysts have given Keros Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Keros Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Keros Therapeutics' next earnings date?

Keros Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for Keros Therapeutics

How were Keros Therapeutics' earnings last quarter?

Keros Therapeutics, Inc. (NASDAQ:KROS) posted its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.60) EPS for the quarter, meeting the consensus estimate of ($0.60).
View Keros Therapeutics' earnings history

What price target have analysts set for KROS?

4 analysts have issued twelve-month target prices for Keros Therapeutics' stock. Their forecasts range from $37.00 to $75.00. On average, they expect Keros Therapeutics' share price to reach $51.00 in the next twelve months. This suggests that the stock has a possible downside of 34.0%.
View analysts' price targets for Keros Therapeutics

Who are some of Keros Therapeutics' key competitors?

What other stocks do shareholders of Keros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE).

Who are Keros Therapeutics' key executives?

Keros Therapeutics' management team includes the following people:
  • Dr. Jasbir Seehra, Pres, CEO, Treasurer, Sec. & Director (Age 65, Pay $679.14k)
  • Dr. Jennifer Lachey Ph.D., Chief Scientific Officer (Age 48, Pay $387.25k)
  • Dr. Claudia Ordonez M.D., Chief Medical Officer (Age 54, Pay $169.26k)
  • Mr. Keith C. Regnante, Chief Financial Officer (Age 50)

When did Keros Therapeutics IPO?

(KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Keros Therapeutics' stock symbol?

Keros Therapeutics trades on the NASDAQ under the ticker symbol "KROS."

Who are Keros Therapeutics' major shareholders?

Keros Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Logos Global Management LP (7.93%), Foresite Capital Management IV LLC (7.00%), BlackRock Inc. (3.25%), Nantahala Capital Management LLC (1.37%), State Street Corp (0.49%) and Point72 Asset Management L.P. (0.40%).
View institutional ownership trends for Keros Therapeutics

Which institutional investors are selling Keros Therapeutics stock?

KROS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Foresite Capital Management IV LLC, and BlackRock Inc..
View insider buying and selling activity for Keros Therapeutics

Which institutional investors are buying Keros Therapeutics stock?

KROS stock was acquired by a variety of institutional investors in the last quarter, including Logos Global Management LP, Altshuler Shaham Ltd, State Street Corp, Telemus Capital LLC, Nantahala Capital Management LLC, Nisa Investment Advisors LLC, California Public Employees Retirement System, and Wells Fargo & Company MN.
View insider buying and selling activity for Keros Therapeutics

How do I buy shares of Keros Therapeutics?

Shares of KROS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Keros Therapeutics' stock price today?

One share of KROS stock can currently be purchased for approximately $77.33.

How big of a company is Keros Therapeutics?

Keros Therapeutics has a market capitalization of $1.56 billion. Keros Therapeutics employs 32 workers across the globe.

What is Keros Therapeutics' official website?

The official website for Keros Therapeutics is www.kerostx.com.

How can I contact Keros Therapeutics?

Keros Therapeutics' mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The company can be reached via phone at 617-314-6297 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.